Extracorporeal Membrane Oxygenation (ECMO) Machine Market By Component (Pumps; Oxygenators; Controllers; Cannula; Heat Exchangers); By Modality (Veno-Arterial [VA] ECMO; Veno-Venous [VV] ECMO; Arterio-Venous [AV] ECMO); By Application (Respiratory Failure; Cardiac Failure; Extracorporeal Cardiopulmonary Resuscitation [ECPR]); By Patient Type (Neonates; Pediatric Patients; Adults); By End-User (Hospitals; Specialty Clinics; Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Size & Overview

The Extracorporeal Membrane Oxygenation (ECMO) Machine Market was valued at $648.6 million in 2024 and is projected to reach $884.2 billion by 2030, growing at a CAGR of 5.3% during the forecast period. The increasing incidence of respiratory and cardiac failure, coupled with rising adoption of ECMO therapy in critical care and emergency medicine, is driving market expansion.

 

According to the Centers for Disease Control & Prevention (CDC), cardiovascular diseases remain the leading cause of death worldwide, accounting for nearly 18 Mn deaths annually. Additionally, the World Health Organization reports that chronic respiratory diseases (CRDs), including COPD and ARDS, affect over 300 million people globally, many of whom require advanced life-support therapies like ECMO. The growing utilization of ECMO in neonatal and pediatric intensive care units (NICUs and PICUs) further supports market growth, as preterm infants with underdeveloped lungs increasingly benefit from veno-venous (VV) ECMO support.

 

Technological advancements, such as miniaturized ECMO systems, integrated monitoring solutions & portable ECMO machines, are enhancing accessibility & improving patient outcomes. The COVID-19 pandemic significantly increased the demand for ECMO therapy, as severe cases of acute respiratory distress syndrome (ARDS) required prolonged oxygenation support. Reports from WHO indicate that ECMO was used in over 20,000 critically ill COVID-19 patients worldwide, demonstrating its vital role in modern critical care. Additionally, the expansion of ECMO training programs & government investments in advanced critical care infrastructure in North America, Europe, and Asia-Pacific are expected to sustain market growth. However, challenges such as high procedural costs, limited skilled professionals, and accessibility barriers in low-income regions remain key restraints. Despite these hurdles, the ECMO market is poised for continuous innovation & wider adoption in cardiac resuscitation, post-operative care, and emergency transport applications, making it a crucial component of the future of critical care medicine.

 

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Dynamics:

Market Drivers:

Rising Incidence of Respiratory and Cardiac Failure

The increasing prevalence of chronic respiratory diseases (CRDs), including COPD and ARDS, along with the growing burden of heart failure, is significantly driving ECMO adoption. According to the World Health Organization, COPD affected over 200 million people globally in 2023, with a rising number of cases requiring ECMO as a last-resort therapy for severe lung function impairment. For example, during the COVID-19 pandemic, ECMO played a crucial role in managing severe cases of acute respiratory distress syndrome (ARDS), boosting market demand.

Advancements in ECMO Technology and Miniaturization

Technological advancements, such as portable ECMO systems & improved pump & oxygenator designs, are enhancing patient outcomes & expanding ECMO’s usability. The launch of compact, transportable ECMO machines allows for their application in ambulances & air medical transport, improving survival rates in critical patients. Companies like Getinge & Medtronic have developed user-friendly ECMO systems with automated monitoring features, reducing the need for highly specialized operators.

 

Market Restraints:

High Cost of ECMO Treatment & Equipment

ECMO therapy remains expensive, limiting accessibility in developing regions. The average cost of an ECMO procedure ranges from $50,000 - $100,000 per patient, depending on the duration of use & associated intensive care unit (ICU) costs. In lower-income countries, limited reimbursement policies further restrict ECMO adoption. For example, many hospitals in Latin America and Africa struggle to afford ECMO programs, impacting market expansion.

Limited Skilled Professionals for ECMO Management

The operation and monitoring of ECMO machines require specialized healthcare personnel, including perfusionists and critical care specialists, creating a workforce shortage. Studies indicate that more than 50% of hospitals in developing nations lack trained ECMO specialists, leading to underutilization of the technology. In India & Southeast Asia, despite rising demand, ECMO adoption remains limited due to training gaps & resource constraints in critical care units.

 

Market Opportunities:

Expanding Applications Beyond Respiratory & Cardiac Support

ECMO is increasingly being explored for new applications, such as extracorporeal cardiopulmonary resuscitation (ECPR) and post-operative recovery in high-risk cardiac surgeries. According to recent clinical studies, ECPR can improve survival rates by up to 30% in patients with out-of-hospital cardiac arrest (OHCA). Leading hospitals, including Mayo Clinic & Cleveland Clinic, are investing in ECMO-based resuscitation protocols, highlighting future growth opportunities.

Growing ECMO Adoption in Emerging Markets

The expansion of healthcare infrastructure & government initiatives in Asia-Pacific, Latin America & the Middle East are creating new growth avenues. Countries like China, India & Brazil are increasing investments in advanced critical care units, enabling ECMO market penetration. China’s National Health Commission is integrating ECMO machines into high-priority tertiary hospitals, reflecting significant market potential in developing regions.

 

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Segmentation: A Comprehensive Overview

By Component

• Pumps

• Oxygenators

• Controllers

• Cannula

• Heat Exchangers

 

By Modality

• Veno-Arterial (VA) ECMO

• Veno-Venous (VV) ECMO

• Arterio-Venous (AV) ECMO

 

By Application

• Respiratory Failure

• Cardiac Failure

• Extracorporeal Cardiopulmonary Resuscitation (ECPR)

 

By Patient Type

• Neonates

• Pediatric Patients

• Adults

 

By End-User

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centers

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Segment Analysis: Growth Trends Across Categories

By Component:

Leading Segment: Oxygenators

Oxygenators account for the largest share in the ECMO machine market. These are critical components of the ECMO system, enabling oxygenation of the patient's blood outside the body during the procedure. The demand for oxygenators is primarily driven by the increasing number of patients requiring ECMO due to respiratory & cardiac failures. As the complexity of ECMO procedures grows, the need for high-performance oxygenators continues to dominate. This segment holds approximately 40% of the market share, making it the most significant component in the ECMO system.

Fastest-Growing Segment: Heat Exchangers

The heat exchanger segment is the fastest-growing in the ECMO machine market, driven by advancements in thermal management & the rising adoption of ECMO in pediatric and neonatal care. Heat exchangers regulate blood temperature, ensuring optimal conditions during treatment. As ECMO usage expands, particularly in critical care settings, the demand for advanced heat exchangers grows rapidly. The CAGR for heat exchangers is projected at 6.5% over the forecast period.

 

By Modality:

Leading Segment: Veno-Arterial (VA) ECMO

Veno-Arterial (VA) ECMO dominates the modality segment, accounting for over 50% of the market share. VA ECMO is primarily used in cardiac failure, where it provides both respiratory & circulatory support. The procedure is crucial for patients suffering from conditions such as severe cardiac arrest or heart failure. The increasing number of cardiac surgeries and life-threatening cardiac conditions contribute to the high demand for VA ECMO systems.

Fastest-Growing Segment: Veno-Venous (VV) ECMO

Veno-Venous (VV) ECMO, used predominantly for respiratory failure cases, is the fastest-growing modality in the ECMO market. This modality offers effective support for patients suffering from acute respiratory distress syndrome (ARDS) & other lung-related issues. As the incidence of respiratory diseases increases, so does the demand for VV ECMO. The CAGR for VV ECMO is estimated at 7.2%, reflecting its growing use in respiratory failure treatments.

 

By Application:

Leading Segment: Respiratory Failure

Respiratory failure is the leading application segment in the ECMO market, driven by the increasing prevalence of conditions such as ARDS, pneumonia, and COVID-19. ECMO has become a critical intervention for severe respiratory failure cases where conventional ventilation techniques are insufficient. This segment holds a market share of 45%, reflecting its critical importance in life-saving treatments.

Fastest-Growing Segment: Extracorporeal Cardiopulmonary Resuscitation (ECPR)

Extracorporeal Cardiopulmonary Resuscitation (ECPR) is the fastest-growing application for ECMO machines. ECPR is used in cases of out-of-hospital cardiac arrest or severe refractory cardiac arrest in hospital settings. With advancements in resuscitation techniques & increasing survival rates for cardiac arrest patients, the demand for ECPR is rising. The CAGR for ECPR is projected to grow at 8.1%, making it a significant area of development for ECMO technology.

 

By Patient Type:

Leading Segment: Adults

The adult patient segment represents the largest share in the ECMO market, as adult patients are the primary recipients of ECMO for both respiratory and cardiac support. Adults with severe cardiovascular diseases, respiratory failure, or post-surgical complications are the largest group treated with ECMO. This segment holds approximately 65% of the market share.

Fastest-Growing Segment: Neonates

The neonate patient segment is the fastest-growing, driven by increasing use in neonatal intensive care units (NICUs) and advances in neonatal ECMO technology. Neonates, especially those born prematurely or with severe respiratory or cardiac issues, benefit from ECMO support. The CAGR for neonatal ECMO is expected to reach 7.8% over the forecast period, reflecting the growing capabilities of neonatal ECMO systems.

 

By End-User:

Leading Segment: Hospitals

Hospitals are the largest end-user for ECMO machines, comprising over 75% of the total market. The demand for ECMO in hospital settings is fueled by the prevalence of acute respiratory and cardiac conditions that require advanced life support. Intensive care units (ICUs) in hospitals are the primary areas where ECMO systems are employed for critical patients.

Fastest-Growing Segment: Ambulatory Surgical Centers

Ambulatory Surgical Centers (ASCs) are the fastest-growing end-user segment for ECMO machines. The rise in outpatient and minimally invasive surgeries requiring short-term ECMO support is contributing to this growth. ASCs benefit from ECMO technology for cases where patients require temporary circulatory or respiratory support during complex surgical procedures. The CAGR for ASCs is estimated at 6.3%.

 

By Region:

Leading Region: North America

North America holds the largest market share for ECMO machines, with the US being the primary contributor. The strong healthcare infrastructure, coupled with high adoption rates of advanced medical technologies & growing demand for ECMO in critical care, places North America in the lead. The region holds approximately 40% of the market share.

Fastest-Growing Region: Asia-Pacific

The APAC region is the fastest-growing for ECMO machines, with countries like Japan, China & India contributing to the surge in demand. The region is witnessing rapid growth in healthcare infrastructure, rising awareness about advanced life support systems, and increasing cases of respiratory and cardiac diseases. The CAGR for the APAC region is projected at 8.5%, driven by advancements in healthcare and increasing adoption of ECMO technology.

 

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Report Coverage

Report Attribute	Details
Forecast Period	2024 – 2032
Market Size Value in 2024	USD 648.6 Million
Revenue Forecast in 2030	[Please Confirm the Correct Value]
Overall Growth Rate	CAGR of 5.3% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Component, By Modality, By Application, By Patient Type, By End-User, By Geography
By Component	Pumps; Oxygenators; Controllers; Cannula; Heat Exchangers
By Modality	Veno-Arterial (VA) ECMO; Veno-Venous (VV) ECMO; Arterio-Venous (AV) ECMO
By Application	Respiratory Failure; Cardiac Failure; Extracorporeal Cardiopulmonary Resuscitation (ECPR)
By Patient Type	Neonates; Pediatric Patients; Adults
By End-User	Hospitals; Specialty Clinics; Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising incidence of respiratory and cardiac failure, increasing adoption of ECMO in critical care, technological advancements
Pricing and Purchase Options	Customized options available

 

Key Players in the Extracorporeal Membrane Oxygenation (ECMO) Machine Market

• Medtronic

• Getinge Group

• LivaNova PLC

• Abbott Laboratories

• Terumo Corporation

• Fresenius Medical Care

• MicroPort Scientific Corporation

• Nipro Corporation

• Eurosets

• ALung Technologies, Inc.

 

Recent Developments

• In September 2024, Medtronic introduced the VitalFlow™ ECMO System, an all-in-one extracorporeal membrane oxygenation solution designed to simplify ECMO procedures. The system aims to provide clinicians with a user-friendly experience, enhancing patient care during critical situations. 

• In August 2020, Terumo Cardiovascular, a subsidiary of Terumo Corporation, partnered with CytoSorbents Corporation to integrate CytoSorb therapy with Terumo's ECMO machines. This collaboration aimed to enhance treatment options for patients undergoing ECMO therapy, particularly in addressing complications such as cytokine storm syndromes.

• In April 2020, LivaNova PLC announced that its cardiopulmonary products received clearance from the U.S. Food & Drug Administration (FDA) for use in ECMO therapy exceeding six hours. This approval allowed for extended application of LivaNova's ECMO devices, broadening treatment possibilities for patients with severe cardiac and respiratory conditions.

 

Future Outlook

The future outlook for the Extracorporeal Membrane Oxygenation (ECMO) machine market remains highly promising, driven by the rising incidence of cardiac and respiratory failure, an aging population, and increasing adoption of ECMO therapy in critical care settings. Technological advancements, including miniaturization of ECMO devices, integration of artificial intelligence (AI) for monitoring & improved biocompatibility materials, are expected to enhance patient outcomes & expand the use of ECMO beyond traditional applications. The growing demand for portable & transportable ECMO systems is also reshaping the market, making life-support technologies more accessible in emergency & pre-hospital settings. Additionally, regulatory approvals for extended ECMO use & increasing investments in ECMO-focused research & clinical trials will further accelerate market growth. However, challenges such as high treatment costs, the need for specialized healthcare professionals, and limited availability in developing regions may hinder widespread adoption. Despite these barriers, strategic partnerships, hospital expansions & the integration of advanced monitoring systems are expected to drive the ECMO market's steady growth, reinforcing its critical role in advanced life-support therapies.